UNC Lineberger Comprehensive Cancer Center | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to Places / Academic & Health Care Centers
UNC Lineberger Comprehensive Cancer Center

UNC Lineberger Comprehensive Cancer Center

UNC Lineberger Building
450 West Drive
Chapel Hill, North Carolina, United States
Phone   Web  
UNC Lineberger Comprehensive Cancer Center’s Multiple Myeloma & Amyloidosis Program treats multiple myeloma, amyloidosis and other plasma cell-related disorders such as solitary plasmacytoma, POEMS syndrome, monoclonal gammopathy of uncertain significance (MGUS), asymptomatic “smoldering” myeloma and Castleman’s disease.
 
UNC’s Multiple Myeloma & Amyloidosis Program offers patients and referring physicians access to a complete range of both diagnostic and therapeutic services for multiple myeloma and other plasma cell disorders. These include chemotherapy, radiation therapy and stem cell transplantation.
 
They ensure that expertly developed care is individualized for each patient and delivered in a well-coordinated and caring manner by incorporating specialists from hematology, medical, radiation oncology, pathology, UNC Imaging and Spine Center, the Bone Marrow Transplant and Cellular Therapy Program, radiology, and oncology nursing into a single patient care team.

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close